ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1461

Modification of Proteins with Malondialdehyde-Acetaldehyde and Citrulline Elicit Antibody Responses in DBA/1J Mice

Peter M. Maloley1, Michael J. Duryee2, Carlos D. Hunter2, James R. O'Dell3, Daniel R. Anderson1, Ted R Mikuls4, Geoffrey M. Thiele1 and Lynell W. Klassen3, 1University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 4Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: citrullination, immune activation and mouse model, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Animal Models - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous studies have shown that proteins modified with malondialdehyde-acetaldehyde (MAA) and/or citrulline (CIT) co-localize in rheumatoid arthritis (RA) synovial tissues, are pro-inflammatory, and promote robust antibody responses that correlate with disease severity in RA. The interaction of MAA and CIT modifications on proteins with respect to immune responses is not currently known.  Thus, the purpose of this study was to first examine the feasibility of co-modifying protein with both MAA and CIT and secondly to evaluate the impact of these modifications on antibody responses.  

Methods:  Human serum albumin (ALB) was modified with MAA (MAA-ALB), CIT (CIT-ALB), MAA then CIT (MAA-CIT-ALB), or CIT then MAA (CIT-MAA-ALB) in order to produce the unique antigens.  Samples were analyzed for MAA adduction using fluorescence and CIT by Western blot.  Protein concentrations were determined and separate groups of mice (n=10 per antigen) were immunized with 25 μg of MAA-ALB, CIT-ALB, MAA-CIT-ALB, or CIT-MAA-ALB weekly for 5 weeks.  At week 6, serum was tested for antibody reactivity to these modifications using ELISA with mouse serum albumin (MSA) used in place of ALB.  This was done to eliminate background reactivity and to assess the reactivity specific to the MAA or CIT epitopes rather than ALB.  Data is expressed in arbitrary units relative to a mouse IgG standard curve, and analyzed by one-way ANOVA.  

Results: MAA levels (by fluorescence) and citrullination (by Western Blot) showed no differences with respect to the amount of modification between the different antigens, and all preparations remained soluble.  Immunization with CIT-ALB produced a significant (P=0.03) antibody response to the MAA epitope with very little antibody to the CIT epitope.  MAA-ALB, CIT-MAA-ALB, and MAA-CIT-ALB immunization significantly (P<0.01) increased the antibody responses to MSA-MAA, MSA-MAA-CIT, and MSA-CIT-MAA compared to immunization with CIT-ALB.  Notably, immunization with CIT-MAA-ALB or MAA-CIT-ALB increased the antibody concentrations 4-fold over MAA immunization alone to all antigens except MSA-CIT. 

Conclusion: Modification of protein with MAA in combination with CIT appears to form a stable protein adduct.  The combination of these two modifications elicits a robust antibody response in mice to MAA or the MAA-CIT antigen regardless of which modification was performed first, but was highly dependent on the presence of the MAA modification to drive the immune response.  These data provide a potential mechanism by which MAA-modification and citrullination of self-proteins conspire to promote the initiation or progression of RA.  Future studies evaluating the T-cell response are under way to understand this unique immune response. 


Disclosure: P. M. Maloley, None; M. J. Duryee, None; C. D. Hunter, None; J. R. O'Dell, Eli Lilly and Company, Medac, Coherus, BMS, GSK, 5; D. R. Anderson, None; T. R. Mikuls, None; G. M. Thiele, None; L. W. Klassen, None.

To cite this abstract in AMA style:

Maloley PM, Duryee MJ, Hunter CD, O'Dell JR, Anderson DR, Mikuls TR, Thiele GM, Klassen LW. Modification of Proteins with Malondialdehyde-Acetaldehyde and Citrulline Elicit Antibody Responses in DBA/1J Mice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/modification-of-proteins-with-malondialdehyde-acetaldehyde-and-citrulline-elicit-antibody-responses-in-dba1j-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modification-of-proteins-with-malondialdehyde-acetaldehyde-and-citrulline-elicit-antibody-responses-in-dba1j-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology